Article

Study identifies factors predicting functional outcome with anti-VEGF therapy in AMD patients

Foveal retinal pigment epithelium autofluorescence (RPE AF) and foveal retinal sensitivity are significant in predicting functional outcome after therapy with anti-vascular epithelial growth factor in patients with age-related macular degeneration, according to Daniel Pauleikhoff, MD, of the Department of Ophthalmology, St Franziskus Hospital, Muenster, Germany.

Foveal retinal pigment epithelium autofluorescence (RPE AF) and foveal retinal sensitivity are significant inpredicting functional outcome after therapy with anti-vascular epithelial growth factor in patients withage-related macular degeneration, according to Daniel Pauleikhoff, MD, of the Department of Ophthalmology, St.Franziskus Hospital, Muenster, Germany.

The prospective study that he discussed also found that an increase in visual acuity can be expected with normalfoveal AF if foveal sensitivity is greater than 4 dB, he added.

The researchers treated 128 patients three times at 4-week intervals with ranibizumab (Lucentis, Genentech).Patients with normal RPE AF were compared with those with changed RPE AF.

Before treatment, both groups had similar distributions of visual acuity. At 3 months after treatment, however,a significant difference existed: logMAR 1.0 was observed in 4% of those with normal AF and in 20% of those withchanged AF.

Changes in visual acuity during therapy differed between the groups. Increased visual acuity was observed in 84%of the normal AF group. Visual acuity was stable in 16% of this group and did not decrease in any members ofthis group.

Measured retinal thickness was similar in both groups. When divided according to foveal sensitivity (below orabove 4 dB), visual acuity also was similar in both groups before therapy. After 3 months, however, despiteobserving a similar reduction in retinal thickness in both groups, researchers observed a significant differencein visual acuity between the groups.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.